Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae

Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.

Saved in:
Bibliographic Details
Main Authors: Tuon,Felipe F., Graf,Maria Esther, Merlini,Alexandre, Rocha,Jaime L., Stallbaum,Suellen, Arend,Lavinia N., Pecoit-Filho,Roberto
Format: Digital revista
Language:English
Published: Brazilian Society of Infectious Diseases 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000100001
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1413-86702017000100001
record_format ojs
spelling oai:scielo:S1413-867020170001000012017-03-06Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant EnterobacteriaceaeTuon,Felipe F.Graf,Maria EstherMerlini,AlexandreRocha,Jaime L.Stallbaum,SuellenArend,Lavinia N.Pecoit-Filho,Roberto Carbapenemase-producing Klebsiella pneumoniae Ventilator-associated pneumonia Risk factors Mortality Treatment Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.info:eu-repo/semantics/openAccessBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious Diseases v.21 n.1 20172017-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000100001en10.1016/j.bjid.2016.09.008
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Tuon,Felipe F.
Graf,Maria Esther
Merlini,Alexandre
Rocha,Jaime L.
Stallbaum,Suellen
Arend,Lavinia N.
Pecoit-Filho,Roberto
spellingShingle Tuon,Felipe F.
Graf,Maria Esther
Merlini,Alexandre
Rocha,Jaime L.
Stallbaum,Suellen
Arend,Lavinia N.
Pecoit-Filho,Roberto
Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
author_facet Tuon,Felipe F.
Graf,Maria Esther
Merlini,Alexandre
Rocha,Jaime L.
Stallbaum,Suellen
Arend,Lavinia N.
Pecoit-Filho,Roberto
author_sort Tuon,Felipe F.
title Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
title_short Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
title_full Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
title_fullStr Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
title_full_unstemmed Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae
title_sort risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant enterobacteriaceae
description Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.
publisher Brazilian Society of Infectious Diseases
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702017000100001
work_keys_str_mv AT tuonfelipef riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT grafmariaesther riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT merlinialexandre riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT rochajaimel riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT stallbaumsuellen riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT arendlavinian riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
AT pecoitfilhoroberto riskfactorsformortalityinpatientswithventilatorassociatedpneumoniacausedbycarbapenemresistantenterobacteriaceae
_version_ 1756416534440312832